Le Lézard3d
NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company
SHELTON, CT / ACCESS Newswire / March 11, 2025 / NanoViricides, Inc. (the "Company"), a clinical-stage global leader developing revolutionary broad-spectrum antiviral drugs that the viruses cannot ...
Business Wire2d
Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral ...
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE ... of new options across multiple drug classes to help those impacted by HIV. Today, we are developing a series of antiviral options designed to ...
5 years since COVID was declared a pandemic, we’re still poorly prepared for the next one
On March 11 2020, as COVID continued to spread rapidly around the globe, the World Health Organization (WHO) officially ...
pharmaphorum1d
EMA clears compassionate use of Gilead’s remdesivir for COVID-19
The EU drugs regulator says Gilead Sciences’ antiviral drug remdesivir should be made available for people seriously ill with COVID-19, despite limited data on its efficacy. The EMA’s human ...
pharmaphorum3d
Dr. B: Expanding the business model from COVID vaccines to antiviral medications
Many requirements accompany the distribution of the drugs to patients, and for a good reason. Pfizer’s Paxlovid and Merck & Co’s Molnupiravir are two oral antiviral treatments authorised for ...
Le Lézard2d
Exein partners with Supermicro to redefine the future of embedded security
Exein, the embedded IoT cybersecurity company, and Supermicro, a global leader in application-optimized total IT solutions, have announced a partnership to redefine embedded security. Exein and ...
C&EN5d
Is there a market for new COVID-19 drugs?
Three antivirals are available in the US today: Pfizer’s Paxlovid, or nirmatrelvir with ritonavir; Gilead Sciences’ Veklury, or remdesivir; and Merck & Co.’s Lagevrio ... by a program that funded ...
Merck releases positive phase 3 data on daily oral HIV drug
In the second trial, which was open label, 95.6% of participants who switched to DOR/ISL maintained viral suppression ...
Merck Plans Regulatory Submission For Two-Drug Regime For HIV Infection By Mid-2025
Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...
Drug may prevent COVID-19 in exposed people within households, major trial finds
An international clinical trial has identified a medication that can help prevent symptomatic COVID-19 in people exposed ...